BC
ARMP icon

Broadfin Capital’s Armata Pharmaceuticals ARMP Stock Holding History

Broadfin Capital’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,943
Closed -$2.2M – 73
2015
Q4 		$2.2M Hold
3,943
– – 0.14% 81
2015
Q3 		$2.18M Buy
+3,943
New +$3.6M 0.12% 81

Other funds holding ARMP

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
MLM
Mount Lucas Management Newtown, Pennsylvania $271M AUM 25.49% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Broadfin Capital's ARMP Position: Q1 2016 in Review

Broadfin Capital sold out of Armata Pharmaceuticals (ARMP) in Q1 2016, closing a stake of 3,943 shares — an estimated $2.2M sold.

Broadfin Capital first reported a position in ARMP in Q3 2015 and held it in 2 quarters. The position peaked at $2.2M in Q4 2015. 19 funds tracked by Wall St. Rank hold ARMP as of Q1 2016.

  • Broadfin Capital reported no remaining Armata Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Broadfin Capital sold 3,943 Armata Pharmaceuticals shares in Q1 2016, an estimated $2.2M.
  • Broadfin Capital first reported a position in Armata Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Broadfin Capital's Armata Pharmaceuticals position peaked at $2.2M in Q4 2015.
  • 19 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.